I think that is plausible. Which makes me wonder
Post# of 147996
If SOC has reduced mortality in the placebo arm, it should also reduce mortality in the treatment arm, right?
So if placebo is 26%, in order to hit the 87 deaths figure, Leronlimab would be 20%, which would mean it's higher than the EIND, which doesn't make sense.
However if a decent number of the 87 are outside of 28 days, the treatment arm % would reduce.